

Revision date: 31-Jan-2012 Version: 1.0 Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222

Emergency telephone number:
CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

Pfizer Ltd Ramsgate Road Sandwich, Kent CT13 9NJ United Kingdom +00 44 (0)1304 616161

Emergency telephone number: International CHEMTREC (24 hours): +1-703-527-3887

Material Name: Topotecan Injection

Trade Name: Not applicable Chemical Family: Not determined

Intended Use: Pharmaceutical product used as Antineoplastic

2. HAZARDS IDENTIFICATION

Appearance: Light yellow to Green Lyophilized powder

Signal Word: DANGER

Statement of Hazard: May damage the unborn child.

May cause genetic defects.

Additional Hazard Information:

Short Term: Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: Adverse effects associated with therapeutic use include decreased white blood cells

(leukopenia), gastrointestinal disturbances, diarrhea, fever, vasodilation, liver enzyme changes,

fatigue, weakness, loss of hair, hypersensitivity reactions.

EU Classification

EU Indication of danger: Toxic to Reproduction: Category 2

Mutagenic: Category 2

EU Hazard Symbols:



EU Risk Phrases:

R61 - May cause harm to the unborn child. R46 - May cause heritable genetic damage. Hazardous Substance. Non-Dangerous Goods.

Australian Hazard Classification

(NOHSC):

PZ01368

Material Name: Topotecan Injection Page 2 of 8
Revision date: 31-Jan-2012 Version: 1.0

2. HAZARDS IDENTIFICATION

Note:

This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the active substance or its intermediates regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Hydrochloric Acid	7647-01-0	231-595-7	C;R35 T;R23	**
Sodium hydroxide	1310-73-2	215-185-5	C;R35	**
Topotecan hydrochloride	119413-54-6	Not Listed	Repr. Cat.2, R61; Mut. Cat.2, R46	3

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	%
Mannitol	69-65-8	200-711-8	Not Listed	*
Tartaric acid	87-69-4	201-766-0	Not Listed	*
Water for injection	7732-18-5	231-791-2	Not Listed	*

Additional Information: * Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety

For the full text of the R phrases mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards

Identification and/or Section 11 - Toxicological Information.

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Material Name: Topotecan Injection Page 3 of 8
Revision date: 31-Jan-2012 Version: 1.0

Fire Fighting Procedures: During all fire fighting activities, wear appropriate protective equipment, including self-

contained breathing apparatus.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

6. ACCIDENTAL RELEASE MEASURES

Health and Safety Precautions: Personnel involved in clean-up should wear appropriate personal protective equipment (see

Section 8). Minimize exposure.

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that

controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

Measures for Environmental

Protections:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to

avoid environmental release.

Additional Consideration for Large

Spills:

Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

General Handling: Restrict access to work area. Designate a change area to facilitate 'good laboratory'

decontamination practices. Ground and bond all bulk transfer equipment. No open handling permitted. All operations should be fully enclosed. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled

with dust collectors, HEPA filtration systems or other equivalent controls.

Storage Conditions: Store as directed by product packaging.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Refer to available public information for specific member state Occupational Exposure Limits.

Hydrochloric Acid

ACGIH Ceiling Threshold Limit: 2 ppm
Australia PEAK 5 ppm
7.5 mg/m³

8 mg/m³ **Bulgaria OEL - TWA Cyprus OEL - TWA**5 ppm
8 mg/m³

Czech Republic OEL - TWA 8 mg/m³
Estonia OEL - TWA 5 ppm

8 mg/m³ **Germany - TRGS 900 - TWAs**2 ppm
3 mg/m³

Germany (DFG) - MAK 2 ppm 3.0 mg/m³

Material Name: Topotecan Injection Page 4 of 8
Revision date: 31-Jan-2012 Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Greece OEL - TWA	5 ppm
	7 mg/m³
Hungary OEL - TWA	8 mg/m ³
Ireland OEL - TWAs	5 ppm
	8 mg/m ³
Italy OEL - TWA	5 ppm
	8 mg/m ³
Japan - OELs - Ceilings	5 ppm
•	7.5 mg/m ³
Latvia OEL - TWA	5 ppm
	8 mg/m ³
Lithuania OEL - TWA	5 ppm
	8 mg/m ³
Luxembourg OEL - TWA	5 ppm
	8 mg/m³
Malta OEL - TWA	5 ppm
	8 mg/m ³
Netherlands OEL - TWA	8 mg/m ³
Poland OEL - TWA	5 mg/m ³
Romania OEL - TWA	5 ppm
	8 mg/m ³
Slovakia OEL - TWA	5 ppm
	8.0 mg/m ³
Slovenia OEL - TWA	5 ppm
	8 mg/m ³
Spain OEL - TWA	5 ppm
	7.6 mg/m ³

Sodium hydroxide

ACGIH Ceiling Threshold Limit: 2 mg/m^3 Australia PEAK 2 mg/m³ 2 mg/m³ Austria OEL - MAKs 2.0 mg/m³ **Bulgaria OEL - TWA** Czech Republic OEL - TWA 1 mg/m^3 Estonia OEL - TWA 1 mg/m³ France OEL - TWA 2 mg/m³ **Greece OEL - TWA** 2 mg/m³ **Hungary OEL - TWA** 2 mg/m³ 2 mg/m^3 Japan - OELs - Ceilings 0.5 mg/m³ Latvia OEL - TWA 2 mg/m^3 **OSHA - Final PELS - TWAs:** Poland OEL - TWA 0.5 mg/m³ 2 mg/m³ Slovakia OEL - TWA Slovenia OEL - TWA 2 mg/m³ 1 mg/m³ **Sweden OEL - TWAs**

Topotecan hydrochloride

Pfizer Occupational Exposure OEB 5 (control exposure to <1 ug/m³)

Band (OEB):

Engineering Controls: Engineering controls should be used as the primary means to control exposures. Use process

containment, local exhaust ventilation, or other engineering controls to maintain airborne levels within the OEB range. All operations should be fully enclosed. No air recirculation permitted.

Material Name: Topotecan Injection Page 5 of 8
Revision date: 31-Jan-2012 Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Environmental Exposure Controls: Refer to specific Member State legislation for requirements under Community environmental

legislation.

Personal Protective Equipment: Refer to applicable national standards and regulations in the selection and use of personal

protective equipment (PPE).

Hands: Wear impervious, disposable gloves as minimum protection (double recommended).

Eyes: Wear safety glasses as minimum protection.

Skin: Wear impervious disposable protective clothing when handling this compound.

Respiratory protection: If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear

an appropriate respirator with a protection factor sufficient to control exposures to the bottom of

the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Lyophilized powder Color: Light yellow to Green

Molecular Formula: Mixture Molecular Weight: Mixture

10. STABILITY AND REACTIVITY

Chemical Stability: Stable under normal conditions of use.

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

11. TOXICOLOGICAL INFORMATION

General Information: The information included in this section describes the potential hazards of the individual

ingredients.

Acute Toxicity: (Species, Route, End Point, Dose)

Mannitol

Rat Oral LD 50 13500 mg/kg Mouse Oral LD 50 22 g/kg

Sodium hydroxide

Mouse IP LD50 40 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Reproduction & Development Toxicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Topotecan hydrochloride

Embryo / Fetal Development Rabbit Intravenous 0.1 mg/kg/day LOAEL Maternal toxicity, Embryotoxicity, Fetotoxicity

Embryo / Fetal Development Rat Intravenous 0.23 mg/kg/day LOAEL Fetotoxicity

PZ01368

Material Name: Topotecan Injection Page 6 of 8
Revision date: 31-Jan-2012 Version: 1.0

11. TOXICOLOGICAL INFORMATION

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Topotecan hydrochloride

In Vitro Mammalian Cell Mutagenicity Human Lymphocytes Positive In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Positive

In Vivo Mouse Bone Marrow Positive

Carcinogen Status: Not listed as a carcinogen by IARC, NTP or US OSHA.

Hydrochloric Acid

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been thoroughly investigated. Releases to the environment

should be avoided.

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Topotecan hydrochloride

Daphnia magna (Water Flea) EC50 48 Hours 61.8 mg/L

Pimephales promelas (Fathead Minnow) EC50 96 Hours 45.7 mg/L

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

EU Indication of danger: Toxic to Reproduction: Category 2

Mutagenic: Category 2

EU Risk Phrases:

R61 - May cause harm to the unborn child. R46 - May cause heritable genetic damage.

Material Name: Topotecan Injection Page 7 of 8
Revision date: 31-Jan-2012 Version: 1.0

15. REGULATORY INFORMATION

EU Safety Phrases:

S22 - Do not breathe dust.

S53 - Avoid exposure - obtain special instructions before use.

OSHA Label:

DANGER

May damage the unborn child. May cause genetic defects.

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Hydrochloric Acid

CERCLA/SARA 313 Emission reporting	1.0 %
CERCLA/SARA Hazardous Substances	5000 lb
and their Reportable Quantities:	2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous	500 lb
TDO-	

TPQs

CERCLA/SARA - Section 302 Extremely Hazardous 5000 lb

Substances EPCRA RQs

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Standard for the Uniform Scheduling
for Drugs and Poisons:

EU EINECS/ELINCS List

Present
Schedule 5
Schedule 6
231-595-7

Mannitol

Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the	Present

obligations of Register:

EU EINECS/ELINCS List 200-711-8

Sodium hydroxide

CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling	Schedule 5
for Drugs and Poisons:	Schedule 6
EU EINECS/ELINCS List	215-185-5

D704000

Material Name: Topotecan Injection Page 8 of 8 Revision date: 31-Jan-2012 Version: 1.0

15. REGULATORY INFORMATION

Tartaric acid

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **EU EINECS/ELINCS List** 201-766-0

Water for injection

Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present **REACH - Annex IV - Exemptions from the** Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

16. OTHER INFORMATION

Text of R phrases mentioned in Section 3

R61 - May cause harm to the unborn child.

R46 - May cause heritable genetic damage.

R23 - Toxic by inhalation. R35 - Causes severe burns.

Publicly available toxicity information. Safety data sheets for individual ingredients. **Data Sources:**

Product Stewardship Hazard Communication Prepared by:

Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet